Great meeting indeed #ESTRO24
Many thanks to ESTRO Anna Kirby and all friends and colleagues 🙏🏽
Looking forward to Matthias Guckenberger presidency

Congratulations prof. Barbara Jereczek-Fossa, as president-elect and Matthias Guckenberger as new president of ESTRO. Thanks Anna Kirby for leading the society in the past 2 years.

Also worth noting that our surgical credentialing was similar to E3311.

Our G3-5 bleeding rate was almost identical to E3311 (and G3 bleeds can easily become G5).

Our positive margin rate was a bit higher...but way lower than at US institutions as a whole (based on NCDB).

- Important QOL differences in some domains
- MDADI LMM curves over time reminiscent of ORATOR

Here are the slides from the ORATOR2 trial. Key takeaways (short 🧵)

- RT meets primary endpoint compared to historical control
- OS and PFS significantly better in RT arm.

REPAINT study from Montefiore Einstein CC Bronx presented at #ESTRO24

➡️ comparable outcomes with dose adapted hypoFx RT.

🚨 Huge difference between Patient reported and Clinician reported outcomes:

E.G. Patient reported Dysphagia 38% vs oesophagitis 3% graded by 👩‍⚕️

Honored to co-chair IASLC-ESTRO joined session with my friend Ben! Outstanding speakers debating RT escalation vs de-escalation in stage III NSLCL. Key: Individualized biology and novel technologies to guide RT dosage with reduced side affects. >1000 attendees ESTRO IASLC

1/

finally, individualization of therapy in stage III #lungcancer at #ESTRO24 by Dr Ohri 🙏🙏🙏 #precisiononcology

What happens after PACIFIC?

Well local failure happens in larger tumors (for which 60-66 Gybis not enough) #radbio 🔥

Joe Y Chang Ben Slotman Jake Scott

Stage III NSCLC in the era of IO and targeted TX, surgery or RT? OS and quality of life are the King. RT dose escalation or de-escalation? Biology is the King. ESTRO/IASLC joined session May 5 -Glasgow ESTRO IASLC Ben Slotman

Welcome to ESTRO24! Hope you're enjoying this beautiful sunny weather in Glasgow! ☀️ #ESTRO24

Let's take your mind on a walk outside the box.
Phase I Clinical Trial of SBRT for Lung Volume Reduction for Severe Emphysema
Max Diehn, MD/PhD Bill Loo MD PhD ⚡️☢️ Stanford Radiation Oncology
At: redjournal.org/article/S0360-…

Fortunately there are now pointers with a very small tip, so the difference can be demonstrated in presentations. If OS increases from 99.5 to 99.75%, the HR is 0.50, correct?

📣 #RTTs ! Participate in our survey on the impact of ESTRO-ACROP #guidelines on positioning, immobilisation, and position verification for #headandneckcancer patients.
👉 Take the survey: bit.ly/4al5IEu
Just 10 mins needed! ⏰ Deadline: 19 April.
#radonc #radiotherapy

PORT is alive ... in thymic carcinoma

After R0 resection
👉OS advantage in stages III–IV, 5y 71.6% vs 45.2%

After R1/2 resection
👉 OS advantage especially in stages III-IV, 5y 53% vs 38% p < 0.001
👉 Too small pts numbers with stages I-II
#radonc
jto.org/article/S1556-…

Don’t miss the opportunity to attend and present at IASLC #WCLC24 SanDiegoCounty Dr. Nina Niu Sanford Jeff Ryckman Shankar Siva Ben Slotman Alex Louie MD, PhD Simon Lo Drew Moghanaki 🐕

Virtual Grand Rounds in #radonc

Pulmonary SBRT in pts with interstitial lung disease: results of the ASPIRE-ILD trial

Presented by
Professor David Palma Dr. David Palma

April 3rd - 17:00 - 17:30 CET

Meeting link 👇
usz.ch/veranstaltunge…

Endorsed by
Deutsche Gesellschaft für Radioonkologie e.V.
ESTRO
SASRO

Great to catch up with friends at the #2024RSS annual meeting in Chicago

The Roaring 20’s theme at the #2024RSS annual meeting in Chicago. With Madhur Garg, Shalom Kalnicki and Simon Lo.

Thought provoking keynote session “AI in Medicine” at the 2024 RSS Scientific Meeting #2024rss

Breaking from #ELCC (discounting a press release…)

🚨 PACIFIC-2 is negative. No improvement with concurrent and adjuvant Durvalumab with chemo radiotherapy in stage III NSCLC

Jeff Bradley, MD presents at #ELCC 24